AKT1 and triple-negative breast carcinoma: On the basis of our data, the treatment of triple negative breast cancer in a non-metastatic stage with an AKT1/2 inhibitor [108] in combination with other established drugs or mTOR inhibitors like RAD001 should be taken forward in further studies.